Literature DB >> 7879644

Positive and negative symptoms of schizophrenia: past, present, and future.

N C Andreasen1, P Nopoulos, S Schultz, D Miller, S Gupta, V Swayze, M Flaum.   

Abstract

The "group of schizophrenias," normally referred to with a single nominative, is phenomenologically heterogeneous. Its symptoms represent multiple psychological domains, including perception, inferential thinking, language, attention, social interaction, emotion expression, and volition. Studies of psychopathology have simplified this complex array in several ways; one has been a subdivision into positive and negative symptoms. Reports by our group and others suggest that the symptoms of schizophrenia fall into three natural dimensions: positive symptoms subdivided into psychotic and disorganized dimensions, while a third negative dimension also emerges. Since these dimensions have impressive consistency across studies, future work must examine their relationship to clinically relevant concepts such as prognosis or etiology and examine four different aspects: longitudinal course, neural mechanisms, relationship to treatment, and interrelationships in other pathological conditions.

Entities:  

Mesh:

Year:  1994        PMID: 7879644     DOI: 10.1111/j.1600-0447.1994.tb05891.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  16 in total

Review 1.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Abnormal cerebellar structure is dependent on phenotype of isolated cleft of the lip and/or palate.

Authors:  Ian DeVolder; Lynn Richman; Amy L Conrad; Vincent Magnotta; Peg Nopoulos
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

3.  Cerebellum structure differences and relationship to speech in boys and girls with nonsyndromic cleft of the lip and/or palate.

Authors:  Amy L Conrad; Scott Dailey; Lynn Richman; John Canady; Michael P Karnell; Eric Axelson; Peg Nopoulos
Journal:  Cleft Palate Craniofac J       Date:  2010-09

4.  Use of a quantitative trait to map a locus associated with severity of positive symptoms in familial schizophrenia to chromosome 6p.

Authors:  L M Brzustowicz; W G Honer; E W Chow; J Hogan; K Hodgkinson; A S Bassett
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

Review 5.  Neurocognitive mechanisms of conceptual processing in healthy adults and patients with schizophrenia.

Authors:  Tatiana Sitnikova; Christopher Perrone; Donald Goff; Gina R Kuperberg
Journal:  Int J Psychophysiol       Date:  2009-12-07       Impact factor: 2.997

Review 6.  The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question.

Authors:  Vina M Goghari; Scott R Sponheim; Angus W MacDonald
Journal:  Neurosci Biobehav Rev       Date:  2009-09-20       Impact factor: 8.989

7.  A computed tomographic study of schizophrenia.

Authors:  N Lal; S C Tewari; P K Dalal; N Kohli; S Srivastava
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

8.  8-Chloro-5-(4-phenethylpiperazin-1--yl)pyrido[2,3-b][1,5]benzoxazepine.

Authors:  Ben Capuano; Ian T Crosby; Craig M Forsyth; Edward J Lloyd; Amelia Vom; Elizabeth Yuriev
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-09-06

Review 9.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

Review 10.  What we know: findings that every theory of schizophrenia should explain.

Authors:  Angus W MacDonald; S Charles Schulz
Journal:  Schizophr Bull       Date:  2009-03-27       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.